Telli Telli ML ML Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer Breast Cancer Res Treat Breast Cancer Res Treat 2018 2018 168 168 3 3 625 625 630 630 10.1007/s10549-017-4624-7 10.1007/s10549-017-4624-7 supplied-pmid 29275435? The gene discussed is BRCA1; the disease is breast carcinoma.